Photochemical decontamination treatment of whole blood or blood components
AssigneeDiamond Scientific Co.
InventorGary P. Wiesehahn
Life of this patent
Estimating the term…
Abstract
Biological compositions are freed of functional polynucleotides by treatment of the biological composition with psoralen derivatives under irradiation conditions in which the proteins retain their original physiological activities and any polynucleotide present is rendered inactive.
Claims32
A method for decontaminating blood components suspected of containing viruses, said blood components being selected from the group consisting of red blood cells, platelets, blood clotting factors, plasma and immunoglobulins, without substantial impairment of the physiological activities of the treated blood components, said method comprising:
- (a) adding to a blood component selected from the group consisting of red blood cells, platelets, blood clotting factors, plasma and immunoglobulins at least one psoralen compound in an amount sufficient to inactivate substantially all contaminating viruses prevent;
- and thereafter
- (b) irradiating said psoralen treated blood component with long wavelength ultraviolet light under operating conditions which maintain the concentrations of reactive oxygen species at levels which do not substantially impair the physiological activity of the treated blood component, and wherein said irradiation is conducted for a time sufficient to inactivate substantially all contaminating viruses present.
A method for decontaminating blood components suspected of containing viruses, said blood components being selected from the group consisting of red blood cells, platelets, blood clotting factors, plasma and immunoglobulins, without substantial impairment of the physiological activity of the treated blood components, said method comprising:
- (a) adding to a blood component selected from the group consisting of red blood cells, platelets, blood clotting factors, plasma and immunoglobulins at least one psoralen compound in a total psoralen concentration of at least 1 ug/ml and not more than 300 ug/ml;
- and thereafter
- (b) passing said psoralen treated blood component through a light beam with a wavelength in the range of 300 nm to 400 nm at an intensity of about 0.1 mw/cm.sup.2 to 5 W/m.sup.2 at a depth of at least 0.025 mm for a total radiation time of about 5 minutes to about 12 hours, wherein said irradiation is conducted under operating conditions which maintain the concentrations of reactive oxygen species at levels which do not substantially impair the physiological activ of the treated blood component.
Dependencies are inferred from the claim text.